drugset / Trial / NCT01392677

Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea

NCT01392677

Phase 3 Completed 311 enrolled AstraZeneca Bristol-Myers Squibb · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study intends to compare the efficacy and safety of dapagliflozin versus placebo in patients with type 2 diabetes who have inadequate glycaemic control on a background combination of metformin and sulfonylurea.

Timeline

Start
2011-10
Primary completion
2013-01
Completion
2013-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule 10 mg Oral